Business
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for
About this update from Biovie Inc.
[{"type":"image","alt":"BioVie, Inc.","displaySize":"","headline":null,"caption":"BioVie, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/74wuLVBY92R9d2c1AJ.QhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a","width":300,"height":79}},"lazy":false},{"type":"text","content":"CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here.","length":580,"tagName":"p"},{"type":"text","content":"The event will provide an update on BioVie's ADDRESS-LC trial evaluating bezisterim (NE3107) for the treatment of long COVID. Bezisterim is a novel, oral, blood-brain barrier–permeable, anti-inflammatory, insulin-sensitizing agent that has shown to selectively inhibit inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators, without inhibiting their homeostatic functions. Chronic neuroinflammation, potentially driven by persisting viral spike protein1,2, is one of the main hypotheses that researchers have proposed to explain the persistence of symptoms in long COVID.","length":589,"tagName":"p"},{"type":"text","content":"A live question and answer session will follow the formal presentations.","length":72,"tagName":"p"},{"type":"text","content":"About Lindsay McAlpine, MD, BScLindsay McAlpine, MD, BSc, is a neuroimmunologist in Division of Neurological Infections and Global Neurology at the Yale University School of Medicine. She founded the NeuroCOVID Clinic at Yale in October 2020 and now directs the clinic. She sees patients with neurologic issues related to Long COVID and patients with multiple sclerosis and autoimmune disorders of the nervous system. She is an investigator in the ...